Don’t make these mistakes in your clinical trial: The most common FDA violations

John Lehmann, Director of Business Development, IMARC

The FDA’s Bioresearch Monitoring (BIMO) inspection program ensures the protection of the rights, safety and welfare of human subjects during clinical research trials.

The most recent results represent findings from more than 1,300 clinical research audits of clinical investigators, sponsors and IRBs for the 2017 fiscal year.

This whitepaper covers the seven most common ones and how you can avoid them.

The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MassDevice.com or its employees.

The post Don’t make these mistakes in your clinical trial: The most common FDA violations appeared first on MassDevice.

from MassDevice https://ift.tt/2y3xGnF